Open Access Highly Accessed Case report

The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I

Patrick Schöffski16*, Christophe M Deroose2, Olivier Gheysens2, Nele Lips2, Koen Slabbaert3, Ben Vancleynenbreugel3, Philippe Moerman4 and Willy E Peetermans5

Author Affiliations

1 General Medical Oncology, UZ Leuven, Leuven, Belgium

2 Nuclear Medicine, UZ Leuven, Leuven, Belgium

3 Urology, UZ Leuven, Leuven, Belgium

4 Pathology, UZ Leuven, Leuven, Belgium

5 General Internal Medicine, UZ Leuven, Leuven, Belgium

6 Department of General Medical Oncology, University Hospitals Leuven, Laboratory of Experimental Oncology, Division of Oncology, Leuven Cancer Institute, Catholic University Leuven, Herestraat 49, Leuven B-3000, Belgium

For all author emails, please log on.

BMC Medical Imaging 2014, 14:19  doi:10.1186/1471-2342-14-19

Published: 29 May 2014



FDG-PET/CT is part of the standard diagnostic management of a patients with a large variety of common and less common malignant tumors, based on the increased glucose metabolism within tumors.

Case presentation

A hybrid fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) was performed in a neurofibromatosis patient to rule out relapse of malignant peripheral nerve sheet tumor. The scan revealed non-malignant neurofibromas, a testis seminoma and hypermetabolic syphilitic granulomata.


This case stresses the need to rule out infectious diseases when atypical hypermetabolic lesions are present.

Syphilis; PET; Fluorodeoyglucose; Neurofibromatosis; Testicular seminoma